Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Deciphera Pharmaceuticals, Inc. (DCPH : NSDQ)
 
 • Company Description   
Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform.

Number of Employees: 280

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.84 Daily Weekly Monthly
20 Day Moving Average: 1,506,921 shares
Shares Outstanding: 66.22 (millions)
Market Capitalization: $784.01 (millions)
Beta: 1.41
52 Week High: $38.91
52 Week Low: $6.51
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 15.29% 29.83%
12 Week 44.74% 59.11%
Year To Date 21.19% 42.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 SMITH STREET
-
Waltham,MA 02451
USA
ph: 781-209-6400
fax: -
deciphera@argotpartners.com http://www.deciphera.com
 
 • General Corporate Information   
Officers
Steven L. Hoerter - President; Chief Executive Officer andDirector
Thomas P. Kelly - Chief Financial Officer
Patricia L. Allen - Director
Frank S. Friedman - Director
John R. Martin - Director

Peer Information
Deciphera Pharmaceuticals, Inc. (CORR.)
Deciphera Pharmaceuticals, Inc. (RSPI)
Deciphera Pharmaceuticals, Inc. (CGXP)
Deciphera Pharmaceuticals, Inc. (BGEN)
Deciphera Pharmaceuticals, Inc. (GTBP)
Deciphera Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 24344T101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 66.22
Most Recent Split Date: (:1)
Beta: 1.41
Market Capitalization: $784.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.62 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.89
Price/Cash Flow: -
Price / Sales: 7.82
EPS Growth
vs. Year Ago Period: 24.53%
vs. Previous Quarter: 47.02%
Sales Growth
vs. Year Ago Period: 16.17%
vs. Previous Quarter: 20.76%
ROE
03/31/22 - -79.96
12/31/21 - -72.17
09/30/21 - -58.56
ROA
03/31/22 - -61.03
12/31/21 - -57.59
09/30/21 - -48.51
Current Ratio
03/31/22 - 3.69
12/31/21 - 3.50
09/30/21 - 5.08
Quick Ratio
03/31/22 - 3.46
12/31/21 - 3.36
09/30/21 - 4.99
Operating Margin
03/31/22 - -279.96
12/31/21 - -306.78
09/30/21 - -300.00
Net Margin
03/31/22 - -279.96
12/31/21 - -306.78
09/30/21 - -300.00
Pre-Tax Margin
03/31/22 - -284.95
12/31/21 - -311.98
09/30/21 - -300.00
Book Value
03/31/22 - 4.10
12/31/21 - 5.21
09/30/21 - 6.51
Inventory Turnover
03/31/22 - 0.25
12/31/21 - 0.32
09/30/21 - 0.36
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©